Difference between revisions of "Acute myeloid leukemia"
Jump to navigation
Jump to search
(Created page with "{{TOC limit|limit=3}} ==Induction therapy (APL, acute promyelocytic leukemia)== ===ATRA, daunorubicin, cytarabine=== ====Regimen==== *All-trans retinoic acid (ATRA) 45 mg/m2...") |
|||
| Line 2: | Line 2: | ||
==Induction therapy (APL, acute promyelocytic leukemia)== | ==Induction therapy (APL, acute promyelocytic leukemia)== | ||
| − | ===ATRA, daunorubicin, cytarabine=== | + | ===ATRA, daunorubicin, cytarabine #1=== |
====Regimen==== | ====Regimen==== | ||
*[[All-trans retinoic acid (ATRA)]] 45 mg/m2/day, divided into two equal doses PO BID, starting day 1 and continuing until remission | *[[All-trans retinoic acid (ATRA)]] 45 mg/m2/day, divided into two equal doses PO BID, starting day 1 and continuing until remission | ||
| Line 10: | Line 10: | ||
'''7-day initial induction chemotherapy, with ongoing use of ATRA''' | '''7-day initial induction chemotherapy, with ongoing use of ATRA''' | ||
| − | + | ====References==== | |
| + | |||
| + | ===ATRA, idarubicin, cytarabine, mitoxantrone #2=== | ||
| + | ====Regimen==== | ||
*[[All-trans retinoic acid (ATRA)]] 45 mg/m2/day, divided into two equal doses PO BID, starting day 1 and continuing until remission | *[[All-trans retinoic acid (ATRA)]] 45 mg/m2/day, divided into two equal doses PO BID, starting day 1 and continuing until remission | ||
*[[Daunorubicin (Cerubidine)]] 50 mg/m2 IV days 1-4 | *[[Daunorubicin (Cerubidine)]] 50 mg/m2 IV days 1-4 | ||
| Line 30: | Line 33: | ||
====References==== | ====References==== | ||
| + | ===ATRA & arsenic=== | ||
| + | ====Regimen==== | ||
| + | *[[All-trans retinoic acid (ATRA)]] 45 mg/m2/day, divided into two equal doses PO BID, starting day 1 and continuing until remission | ||
| + | *[[Arsenic trioxide (Trisenox)]] 0.15 mg/kg IV daily, starting day 1 and continuing until remission | ||
| + | |||
| + | ====References==== | ||
| + | |||
| + | ==Induction therapy (AML, acute myeloid leukemia)== | ||
| + | |||
| + | ==Consolidation therapy (APL, acute promyelocytic leukemia)== | ||
| + | |||
| + | ===Daunorubicin & cytarabine=== | ||
| + | ====Regimen==== | ||
| + | *[[Daunorubicin (Cerubidine)]] 60 mg/m2 IV on days 1-3 | ||
| + | *[[Cytarabine (Cytosar)]] 200 mg/m2 IV on days 1-7 | ||
| + | |||
| + | '''7-days of therapy, THEN''' | ||
| + | |||
| + | *[[Daunorubicin (Cerubidine)]] 45 mg/m2 IV on days 1-3 | ||
| + | *[[Cytarabine (Cytosar)]] 1500-2000 mg/m2 IV every 12 hours on days 1-7 | ||
| + | *5 doses of intrathecal chemotherapy | ||
| + | '''7-days of therapy''' | ||
| + | ====References==== | ||
| − | == | + | ===Arsenic, ATRA, daunorubicin=== |
| + | ====Regimen==== | ||
| + | *[[Arsenic trioxide (Trisenox)]] 0.15 mg/kg IV days 1-5, 8-12, 15-19, 22-26, 29-33 | ||
| + | |||
| + | '''5-week cycles x 2 cycles, THEN''' | ||
| + | |||
| + | *[[All-trans retinoic acid (ATRA)]] 45 mg/m2/day, divided into two equal doses PO BID, starting days 1-7 | ||
| + | *[[Daunorubicin (Cerubidine)]] 50 mg/m2 IV days 1-3 | ||
| + | |||
| + | '''7-day cycles x 2 cycles''' | ||
| + | |||
| + | ====References==== | ||
| + | |||
| + | ===ATRA, idarubicin, cytarabine, mitoxantrone=== | ||
| + | ====Regimen==== | ||
| + | *[[All-trans retinoic acid (ATRA)]] 45 mg/m2/day, divided into two equal doses PO BID, days 1-15 | ||
| + | *[[Idarubicin (Idamycin)]] 5 mg/m2 IV days 1-4 | ||
| + | *[[Cytarabine (Cytosar)]] 1000 mg/m2 IV days 1-4 | ||
| + | |||
| + | '''15-day cycle, THEN''' | ||
| + | |||
| + | *[[All-trans retinoic acid (ATRA)]] 45 mg/m2/day, divided into two equal doses PO BID, days 1-15 | ||
| + | *[[Mitoxantrone (Novantrone)]] 10 mg/m2 IV days 1-5 | ||
| + | |||
| + | '''15-day cycle, THEN''' | ||
| + | |||
| + | *[[All-trans retinoic acid (ATRA)]] 45 mg/m2/day, divided into two equal doses PO BID, days 1-15 | ||
| + | *[[Idarubicin (Idamycin)]] 12 mg/m2 IV day 1 | ||
| + | *[[Cytarabine (Cytosar)]] 450 mg/m2, divided into three equal doses IV every 8 hours, days 1-4 | ||
| + | |||
| + | '''15-day cycle''' | ||
| + | |||
| + | ====References==== | ||
| − | ==Consolidation therapy== | + | ==Consolidation therapy (AML, acute myeloid leukemia)== |
==Relapse therapy== | ==Relapse therapy== | ||
Revision as of 02:05, 20 February 2012
Induction therapy (APL, acute promyelocytic leukemia)
ATRA, daunorubicin, cytarabine #1
Regimen
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, starting day 1 and continuing until remission
- Daunorubicin (Cerubidine) 60 mg/m2 IV days 1-3
- Cytarabine (Cytosar) 200 mg/m2 IV days 1-7
7-day initial induction chemotherapy, with ongoing use of ATRA
References
ATRA, idarubicin, cytarabine, mitoxantrone #2
Regimen
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, starting day 1 and continuing until remission
- Daunorubicin (Cerubidine) 50 mg/m2 IV days 1-4
- Cytarabine (Cytosar) 200 mg/m2 IV days 1-7
7-day initial induction chemotherapy, with ongoing use of ATRA
References
AIDA
AIDA: ATRA, IDArubicin
Regimen
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, starting day 1 and continuing until remission
- Idarubicin (Idamycin) 12 mg/m2 IV days 2, 4, 6, 8
8-day initial induction chemotherapy, with ongoing use of ATRA
References
ATRA & arsenic
Regimen
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, starting day 1 and continuing until remission
- Arsenic trioxide (Trisenox) 0.15 mg/kg IV daily, starting day 1 and continuing until remission
References
Induction therapy (AML, acute myeloid leukemia)
Consolidation therapy (APL, acute promyelocytic leukemia)
Daunorubicin & cytarabine
Regimen
- Daunorubicin (Cerubidine) 60 mg/m2 IV on days 1-3
- Cytarabine (Cytosar) 200 mg/m2 IV on days 1-7
7-days of therapy, THEN
- Daunorubicin (Cerubidine) 45 mg/m2 IV on days 1-3
- Cytarabine (Cytosar) 1500-2000 mg/m2 IV every 12 hours on days 1-7
- 5 doses of intrathecal chemotherapy
7-days of therapy
References
Arsenic, ATRA, daunorubicin
Regimen
- Arsenic trioxide (Trisenox) 0.15 mg/kg IV days 1-5, 8-12, 15-19, 22-26, 29-33
5-week cycles x 2 cycles, THEN
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, starting days 1-7
- Daunorubicin (Cerubidine) 50 mg/m2 IV days 1-3
7-day cycles x 2 cycles
References
ATRA, idarubicin, cytarabine, mitoxantrone
Regimen
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, days 1-15
- Idarubicin (Idamycin) 5 mg/m2 IV days 1-4
- Cytarabine (Cytosar) 1000 mg/m2 IV days 1-4
15-day cycle, THEN
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, days 1-15
- Mitoxantrone (Novantrone) 10 mg/m2 IV days 1-5
15-day cycle, THEN
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, days 1-15
- Idarubicin (Idamycin) 12 mg/m2 IV day 1
- Cytarabine (Cytosar) 450 mg/m2, divided into three equal doses IV every 8 hours, days 1-4
15-day cycle